Home  |   Equities  |   Indexes  |   Commodities  |   Forex  |   News  |   Analysis  |   Top/Flop  |   Screening  |   Forums
May 25, 2012 10:53 pm US/Eastern
Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX   US64125C1099

Real time Streaming quotes -
 
Delayed Quote. Delayed Nasdaq - 05/25 04:00:01 pm
6.5 USD   +0.31%
05/04 NEUROCRINE BIOSCIENCES, INC.: Neurocrine Biosciences To Present At The Deu..
05/02 NEUROCRINE BIOSCIENCES, INC.: Neurocrine Biosciences Reports First Quarter..
05/01 NEUROCRINE BIOSCIENCES, INC.: Neurocrine Biosciences Announces Conference ..
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
 

Neurocrine Biosciences, Inc. : Neurocrine Biosciences Announces Conference Call and Webcast To Present Fourth Quarter and Year-End 2011 Financial Results

02/02/2012 | 03:50pm

SAN DIEGO, Feb. 2, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2011 financial results after the Nasdaq market closes on Wednesday, February 8, 2012. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, February 8, 2012 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Participants can access the live conference call by dialing 800-894-5910 (US) or 785-424-1052 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 800-688-9445 (US) or 402-220-1371 (International) using the conference ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

 
React to this article
Latest news on NEUROCRINE BIOSCIENCES, I
05/04 Neurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care C..
05/02 Neurocrine Biosciences Reports First Quarter 2012 Results
05/01 Neurocrine Biosciences Announces Conference Call and Webcast to Present First Qu..
04/25 Neurocrine Biosciences Announces Conference Call and Webcast to Present First Qu..
03/27 Neurocrine Biosciences to Present at the 11th Annual Needham Healthcare Conferen..
03/27 Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2..
03/26 Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment..
03/07 Neurocrine Biosciences to Present at The 24th Annual Roth Conference
02/29 Neurocrine Biosciences to Present at the 32nd Annual Cowen Health Care Conferenc..
02/21 Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
Advertisement
Chart
Duration : Period :
Neurocrine Biosciences, I Technical Analysis Chart | NBIX | US64125C1099 | 4-Traders
Income Statement Evolution
Neurocrine Biosciences, I : Income Statement Evolution
More Financials
Advertisement